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Available online 26 October 2011Abstract Human embryonic stem (hES) cells have the dual ability to self-renew and differentiate into specialized cell types.
However, in order to realize the full potential of these cells it is important to understand how the genes responsible for their
unique characteristics are regulated. In this study we examine the regulation of the tropomyosin-related kinase (TRK) genes
which encode for receptors important in hES cell survival and self-renewal. Although the TRK genes have been studied in many
neuronal cell types, the regulation of these genes in hES cells is unclear. Our study demonstrates a novel regulatory relationship
between the TRKC gene and the transcription factor SOX2. Our results found that hES cells highly express full-length and truncated
forms of the TRKC gene. However, examination of the related TRKB gene showed a lower overall expression of both full-length and
truncated forms. Through RNA interference, we knocked down expression levels of SOX2 in hES cells and examined the expression
of TRKC, as well as TRKB. Upon loss of SOX2 we found that TRKC mRNA levels were significantly downregulated but TRKB levels
remained unchanged, demonstrating an important regulatory dependence on SOX2 by TRKC. We also found that TRKC protein
levels were also decreased after SOX2 knock down. Further analysis found the regulatory region of TRKC to be highly conserved
amongmanymammals with potential SOX bindingmotifs. We confirmed a specific binding motif as a site that SOX2 utilizes to
directly interact with the TRKC regulatory region. In addition, we found that SOX2 drives expression of the TRKC gene by
activating a luciferase reporter construct containing the TRKC regulatory region and the SOX binding motif.
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doi:10.1016/j.scr.2011.10.003because of their unique abilities to differentiate into special-
ized cell types and to self-renew indefinitely. However, un-
derstanding how hES cells regulate these distinct properties
is essential in reaching the full potential of these cells. A
number of key factors have proven to play an important role
in the maintenance of pluripotency and self-renewal including
the POU-domain transcription factor OCT4, the homeobox
containing transcription factor NANOG, and the high-mobility
group transcription factor SOX2 (Boyer et al., 2005). In a
207Regulation of TRKC by SOX2previous study, we showed that SOX2 is essential in preserving
pluripotency in hES cells by maintaining the expression of
OCT4, NANOG, and SOX2 as well as a number of downstream
target genes (Fong et al., 2008). Many of these downstream
target genes regulated by SOX2, OCT4, and NANOG were
shown to be important for ES cell pluripotency and self-
renewal (Boyer et al., 2005; Loh et al., 2006; Wang et al.,
2006). However, the precise mechanisms by which these
target genes are regulated remain unclear.
The TRK (also known as NTRK) genes encode a family of
receptor tyrosine kinases that play important roles in regulat-
ing neuronal cell fate specification, proliferation, growth, and
survival (Lei and Parada, 2007). The three members of this re-
ceptor family, TRKA, TRKB, and TRKC, are activated when
bound to a specific group of nerve growth factor (NGF)-related
neurotrophins: NGF, brain-derived neurotrophic factor (BDNF),
neurotrophin 3 (NT3), and neurotrophin 4 (NT4) (Lei and
Parada, 2007; Huang and Reichardt, 2003). Activation of
these receptors initiates several downstream signaling path-
ways including the PI3K/Akt and Ras/MEK/MAPK pathways.
Stimulation of these pathways is essential for proper develop-
ment of the central nervous system in neuronal cells (Tauszig-
Delamasure et al., 2007). Recently, it was found that hES cells
express the receptors TRKB and TRKC and when bound to their
respective ligands, BDNF, NT3, and NT4, can increase clonal
cell survival by up to 36-fold (Pyle et al., 2006).
The discovery of these TRK receptors in hES cells has been
an important finding in facilitating the growth and clonal
survival of hES cells in less than optimal conditions. These
conditions can involve the dissociation of hES cells into single
cells for genetic manipulation which often results in massive
cell death. Therefore, the identification and study of genes
important for hES cell survival would greatly increase the effi-
ciency of many genetic manipulation techniques.
Given the expression of TRKB and TRKC in hES cells and
their importance in improving clonal cell survival, it would
be valuable to gain a better understanding of how these
genes are regulated. A number of transcription factors have
been implicated in the regulation of the TRK genes in differ-
entiated cells, such as Wilms' tumor gene-1 (WT1) and brain-
specific homeobox/POU domain protein 3A (BRN3A) in neuro-
nal cells (Wagner et al., 2005; Huang et al., 1999). However,
the transcription factors regulating the TRKB and TRKC genes
in hES cells remain unidentified.
In hES cells, SOX2 is a key factor in the maintenance of
pluripotency and self-renewal. It is one of the most studied
proteins of the SOX family (Kamachi et al., 2000). In addition
to maintaining hES cell self-renewal and pluripotency, SOX2
is also important in determining early cell-fate decisions in
the precursor cells of the developing central nervous system
(Avilion et al., 2003).
In this study we present a novel regulatory interaction be-
tween SOX2 and theTRKC gene.We show that SOX2 is important
for TRKC expression as the loss of SOX2 effectively decreases
TRKC expression. We also find that SOX2 regulates expression
by directly interacting with SOX-specific binding motifs within
the TRKC regulatory region. We demonstrate that these sites
are conserved among several mammalian species and are im-
portant for TRKC gene transcription. Our study is the first to
identify a role for SOX2 in the regulation of the TRKC gene in
hES cells and suggests a pathway by which SOX2 regulates
the maintenance of the stem cell state in these cells.Results
hES cells express splice variants of the TRKB
and TRKC genes
Although previous studies have shown that hES cells express
the genes for both TRKB and TRKC (Pyle et al., 2006), we
sought to further characterize the genes by examining the
expression of alternatively spliced forms in hES cells. Analysis
by RT-PCR found that the genes can generate mRNAs for both
full-length and truncated isoforms of the receptors. In H9 hES
cells, a higher expression level of the full-length splice variant
of TRKC (TRKC-TK+) was observed in contrast to full-length
splice variant TRKB (TRKB-TK+) (Fig. 1). Similarly, the trun-
cated variant of TRKC (TRKC-TK-) was also expressed at a
higher level in comparison to the TRKB truncated splice vari-
ant (TRKB-TK-) in hES cells. Randomly differentiated hES
cells in the form of embryoid bodies (EB) were used as a posi-
tive control. The EBs expressed both full-length and truncated
splice variants of TRKB and TRKC. No expression of any isoform
of TRKB or TRKCwas observed in mouse embryonic fibroblasts
(MEFs) indicating that the expression of TRKB and TRKC was
specific to hES cells. The expression of TRKA, another member
of the TRK family, was also examined and no detectable levels
were observed by RT-PCR (data not shown).
SOX2 downregulates expression of TRKC but not TRKB
In order to determine if there might be a regulatory relation-
ship between SOX2 and the TRKB and TRKC genes, RNA inter-
ference was used to knock down SOX2 mRNA levels in H9 hES
cells. hES cells were transfected with either an siRNA target-
ing SOX2 or β-2-MICROGLOBULIN (β2M), an siRNA previously
used as a negative control (Fong et al., 2008; Matin et al.,
2004). The expression levels of TRKB and TRKC were then an-
alyzed by quantitative real time-PCR (qRT-PCR). As shown in
Fig. 2A, using the SOX2 siRNA, SOX2 expression levels were
reduced to 37% in comparison to the β2M siRNA sample and
the no siRNA control. After SOX2 knock down, SOX2 protein
levels were also analyzed by Western blot. The results
show marked reduction of SOX2 protein compared to the
no siRNA and β2M siRNA controls (Fig. 2B). The blot was
also probed with a β-ACTIN antibody to confirm that equal
amounts of protein were loaded in each lane. The expres-
sion of the TRK receptors, which included analysis of both
forms, were examined in hES cells upon loss of SOX2. SOX2
knock down significantly downregulated levels of TRKC to
approximately 46% compared to the expression levels seen
in the β2M siRNA sample and the no siRNA control (Fig. 2A).
Expression levels of TRKB, however, were not affected by
the loss of SOX2. These results indicate that loss of SOX2
significantly downregulates expression of TRKC but not the
expression of TRKB. Because of the high expression of
TRKC compared to TRKB in hES cells and the significant down-
regulation of TRKC upon SOX2 knock down, we chose to focus
solely on the role of SOX2 in the regulation of TRKC for the re-
mainder of the experiments in this study.
We further examined TRKC levels after SOX2 knock down by
immunocytochemistry. hES cells transfected with the SOX2
siRNA displayed a noticeable reduction in TRKC staining when
compared to the no siRNA and β2M siRNA samples (Fig. 2C).
Figure 1 H9 hES cells express splice variants of the TRKB and
TRKC genes. RT-PCR analysis of hES cells show higher expression
levels of both the full-length (TK+) and truncated (TK−) forms
of the TRKC gene than either form of TRKB. Embryoid bodies
(EBs), used as a positive control, expressed all forms of TRKB
and TRKC. MEFs did not express any form of TRKB or TRKC. β-
ACTIN was used as a template loading control.
Figure 2 SOX2 knock down results in downregulation of TRKC. (A
siRNA and cultured for four days following nucleofection. qRT-PCR
decrease in TRKC expression but not TRKB expression with the lo
significant effect on TRKB or TRKC expression. Relative expressio
no siRNA. The asterisks (*) indicate values are statistically signific
sented as means±SE with n=3. Statistical t test analysis was perfor
ysis of SOX2 protein following SOX2 knock down shows a noticeab
samples. Equal loading and transfer was confirmed by probing blo
of hES cells transfected with SOX2 siRNA displays reduced staining
with the loss of SOX2.
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tened, dispersed appearance after the loss of SOX2, a result
consistent with our previous findings (Fong et al., 2008).The TRKC Regulatory Region Contains SOX Binding
Sites
Given that the expression of TRKC is dependent on SOX2
expression, we wanted to determine if SOX2 was directly
regulating TRKC expression by physically interacting with
the regulatory region. Through TRANSFAC analysis two poten-
tial SOX binding sites were identified within 2.0 kb of the
TRKC transcription start site (Matys et al., 2006) (Fig. 3A).
Comparison of these sequences with experimentally-proven
SOX binding motifs revealed these sites to be possible SOX2
binding sites. SOX Site A (Site A), located approximately
88 bp upstream and proximal to the start codon, contains
the SOX2 binding sequence TCTTTGTT. This sequence con-
tains the core motif CTTTGT that can be bound by proteins
of the HMG-box family of which SOX2 is a member (Nasrin
et al., 1991). This sequence was also identified as a func-
tional SOX2 binding site for the regulation of FGF-4 (Yuan) hES cells were nucleofected with either a β2M siRNA or SOX2
analysis of the expression levels of TRKB and TRKC showed a
ss of SOX2. Cells nucleofected with the β2M siRNA showed no
n levels were calibrated in relation to cells transfected with
ant compared to cells transfected with no siRNA. Data is pre-
med with a p value b0.05 as significant. (B) Western blot anal-
le decrease in SOX2 compared to the no siRNA and β2M siRNA
ts with a β-ACTIN antibody. (C) Immunocytochemical analysis
of TRKC (green). A marked change in morphology is also seen
Figure 3 The TRKC regulatory region contains conserved SOX binding sites. (A) A schematic of the TRKC regulatory region shows
two potential SOX2 binding sites upstream of the transcription start site (+1): SOX Site A at −88 bp and SOX Site B at −1.9 kb. (B) An align-
ment of the TRKC promoter in four mammals (human, rhesus monkey, mouse and rat) shows that the SOX binding sites are completely
conserved.
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and ~1.9 kb from the start codon, contains the SOX2 binding
sequence TTCAATG. This sequence conforms to the SOX
consensus sequence (A/T)(A/T)CAA(A/T)G (Harley et al.,
1994). This consensus sequence was also used to identify a
SOX2 binding site in a previous study on the regulation of
Oct4 by Sox2 (Okumura-Nakanishi et al., 2005). The presence
of these two potential SOX2 binding motifs within these
regions suggests that it may directly interact with TRKC to
exert its regulatory effects.
The SOX binding sites on TRKC are conserved
in mammals
In order to determine the functional importance of the SOX
binding sites, conservation of these motifs was determined
among four mammalian species. The TRKC regulatory regions
of the human, rhesus monkey, mouse, and rat genomes were
aligned by submitting approximately 2.0 kb of the DNA se-
quence upstream of the start codon to the Mobyle server
using the clustalw service (http://mobyle.pasteur.fr) (Neron
et al., 2009). Comparison of these genomes showed conserva-
tion of Site A and Site B (Fig. 3B), as well as the initiator
element and the start codon (data not shown). The significant
sequence homology suggests that regulation of TRKC expres-
sion by SOX2 may be conserved among mammals.
SOX2 binds to TRKC in hES cells
To assess the interaction of SOX2 with the potential binding
sites Site A and Site B, chromatin immunoprecipitation (ChIP)assays were performed in H9 hES cells. Genomic fragments
bound by SOX2 and approximately 500 bp in size as analyzed
by PCR were immunoprecipitated with a SOX2-specific anti-
body. The immunoprecipitated DNA was then amplified by
PCR and qRT-PCR using primers flanking the two SOX binding
sites on the TRKC regulatory region (Fig. 3A). Samples immu-
noprecipitated with normal goat IgG and mock samples
containing no antibody were used to determine the level
of non-specific antibody binding. Samples immunoprecipi-
tated with the SOX2 antibody efficiently amplified genomic
DNA containing Site A by PCRwhen compared to the amplifica-
tion of input samples containing total DNA (Fig. 4A). However,
no detectable binding of SOX2 on Site B was seen. Samples
immunoprecipitated with normal goat IgG yielded little to no
signal after amplification for Site A or Site B. Similar PCR
results were obtained in the mock ChIP samples. The binding
of SOX2 to Site A was further confirmed by qRT-PCR. An
enrichment of approximately 30-fold above the IgG and
mock ChIP samples was seen when using primers flanking
Site A (Fig. 4B). Analysis of Site B by qRT-PCR resulted in
minimal amplification of this site at approximately 12-fold
enrichment over mock and IgG ChIP samples which was less
than that observed at Site A. A negative control region (NC Re-
gion) located 1.5 kb upstream of the start site and containing
no potential or known SOX binding sites was also analyzed to
check for specificity of SOX2 binding to Site A and Site B. No
detectable binding of SOX2 was seen at this region by PCR
and only a slight enrichment of 5-fold was seen above the
mock and IgG ChIP samples by qRT-PCR. These results demon-
strate that SOX2 is indeed specifically bound to TRKC at a re-
gion that encompasses Site A and to a lesser extent at a
region that encompasses Site B.
Figure 5 The TRKC-LUC reporter vectors are functional in hES
cells. (A) Four different luciferase reporter vectors were used in
the luciferase assays. The TRKC-LUC Site A+B vector contains the
full-length promoter and wild-type SOX Site A and Site B. The
TRKC-LUC Site A also contains the full-length promoter and only
SOX Site A. Site A was deleted in the TRKC-LUC delA vector but
TRKC promoter was kept intact. The EMPTY-LUC vector is a
promoter-less reporter. (B) hES cells were transfected with the
TRKC-LUC Site A+B, TRKC-LUC Site A, TRKC-LUC delA, or EMPTY-
LUC vector. The top bar represents cells transfected with the
TRKC-LUC Site A+B reporter which exhibited approximately 1.8-
fold change in luciferase activity. Cells transfected with the
TRKC-LUC Site A reporter (second bar) displayed about 5.5-fold
change in luciferase activity while deletion of Site A (third bar)
resulted in a decrease of luciferase activity to approximately
2-fold. The EMPTY-LUC vector (fourth bar) was used to normalize
the activity of the other reporter vectors.
Figure 4 SOX2 binds to theTRKC regulatory region. (A) PCR anal-
ysis of ChIP DNA shows amplification of SOX Site A but not Site B
in samples immunoprecipitated with a SOX2 antibody. Little to
no amplification of either Site A or Site B was observed in IgG or
mock ChIP samples. No amplification was seen in any ChIP sam-
ple of the NC Region. (B) qRT-PCR analysis of ChIP DNA specific for
SOX Site A shows a 30-fold enrichment of SOX2-bound DNA com-
pared to the IgG ChIP and mock ChIP. Approximately 12- and 5-
fold enrichment of Site B and NC Region, respectively, was also
seen compared to the IgG ChIP and mock ChIP. ChIP experi-
ments were carried out in triplicate. Error bars represent stan-
dard error of the mean.
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promoter activity
To examine the activity of SOX2 on the TRKC regulatory
region, we constructed three luciferase reporter constructs
(Fig. 5A). TRKC-LUC Site A+B contains the TRKC promoter
and both Site A and Site B, TRKC-LUC Site A contains the
TRKC promoter and only Site A, and TRKC-LUC Site delA also
contains the TRKC promoter but with a deletion of Site A.
Initially, luciferase assays were performed in hES cells to
ensure that the luciferase reporter vectors were properly
functioning. hES cells were transfected with one of the
three luciferase reporter constructs and its activity was
compared to that seen from the promoter-less EMPTY-LUC
vector. hES cells transfected with the TRKC-LUC Site A+B
reporter demonstrated a minimal increase in luciferase ac-
tivity of 1.8-fold compared to the EMPTY-LUC, while hES
cells transfected with the TRKC-LUC Site A reporter demon-
strated an approximately 5.5-fold increase in luciferase ac-
tivity (Fig. 5B). Deletion of Site A from the promoter,
however, displayed greatly decreased luciferase activity
compared to TRKC-LUC Site A. The activity seen in hES
cells transfected with EMPTY-LUC was used to normalizethe activity from the three other reporter constructs. The
results from these initial luciferase assays in hES cells
show that the TRKC promoter including Site A is a fully func-
tional reporter construct. Deletion of Site A, however, was
able to dramatically reduce activity to approximately 2-
fold compared to the empty vector. Inclusion of Site B in
the reporter vector did not seem to greatly increase the
activity indicating that there may be an inhibitory effect
caused by repressors present in hES cells.
After verifying the activity of the reporter constructs in
hES cells, luciferase assays were then conducted in HFF-1
cells with and without SOX2 overexpression to determine if
SOX2 could activate the TRKC promoter. Expression of SOX2
was confirmed in HFF-1 cells by Western blotting (Fig. 6A).
The TRKC-LUC reporter constructs were next transfected
into HFF-1 cells with the SOX2 expression vector. The fold-
change in luciferase activities was compared to cells trans-
fected with the respective reporter vector and the empty
overexpression vector (EMPTY-CMV) containing no SOX2
cDNA. The fold change in luciferase activity in these control
cells was set to a value of 1. Overexpression of SOX2 in cells
transfected with the TRKC-LUC Site A+B reporter vector in-
creased luciferase activity by approximately 2-fold when
211Regulation of TRKC by SOX2compared to cells transfected with the reporter vector and
EMPTY-CMV vector (Fig. 6B). Cells transfected with the
TRKC-LUC Site A exhibited a fold change in luciferase activity
of more than 2.5-fold when SOX2 was overexpressed. In cells
transfected with the TRKC-LUC Site delA reporter and the
SOX2 expression vector, the luciferase activity was reduced
to the level of the control. The activity of cells transfected
with the EMPTY-LUC vector and no DNA was also assayed and
found to exhibit low levels of luciferase activity compared to
their respective controls. Our results indicate that SOX2 ex-
pression is sufficient to drive expression of the TRKC gene
and likely utilizes Site A on the promoter region to carry outFigure 6 The SOX Site A binding site is important for TRKC ex-
pression. (A) Western blot analysis of HFF-1 cells transfected with
the pBKCMV-SOX2 vector shows expression of the SOX2 protein.
SOX2 was not observed in cells transfected with the empty expres-
sion vector or no vector. Equal loading and transfer was confirmed
by probing blots with a β-ACTIN antibody. (B) Luciferase assays in
HFF-1 cells show that SOX2 is required for activation of the TRKC
promoter. Cells were transfected with a luciferase reporter vector
containing the TRKC promoter and SOX Site A and Site B (TRKC-LUC
Site A+B), the TRKC promoter and SOX Site A (TRKC-LUC Site A), or
the TRKC promoter with deleted SOX Site A (TRKC-LUC Site delA)
either with or without the SOX2 overexpression vector. Co-
transfection of the SOX2 overexpression vector with the TRKC-
LUC Site A+B reporter resulted in a 2.0-fold increase in luciferase
activity compared to cells transfectedwith the empty overexpres-
sion vector. Cells transfected with the TRKC-LUC Site A reporter
and the SOX2 overexpression vector exhibited approximately
2.5-fold change in luciferase activity. There was no significant
change in luciferase activity from the TRKC-LUC delA reporter
with SOX2 overexpression. All luciferase activities were compared
to cells transfected with the EMPTY-CMV vector and the respec-
tive reporter construct (value set at 1).its regulatory effects, as its deletion severely diminishes the
transcriptional activity on the promoter.Discussion/conclusions
The expression of the TRK receptors in hES cells proved to be
an important finding in improving single cell culture condi-
tions. The dissociation of hES cells into single cells for genet-
ic manipulations renders them particularly susceptible to
apoptosis. Previous studies have found that the disruption
of E-cadherin signaling responsible for cell–cell interactions
may be the cause for single cell death (Xu et al., 2010). The
addition of the ligands of TRKB and TRKC, however, is able to
improve clonal cell survival in suboptimal growth conditions,
such as during genetic manipulations (Hohenstein et al.,
2008). Although the genes encoding the TRK receptors are
well studied in neuronal cells and play important roles in
cell fate determination, growth and proliferation, they are
not well-studied in hES cells. Due to the receptors' role in
improving hES cell survival, understanding how the genes for
the receptors are regulated would enhance our knowledge of
hES cell biology.
The transcription factor SOX2 was shown to be essential
in maintaining pluripotency and self-renewal in hES cells.
Downregulation of this gene results in the loss of expression
of many genes important in preserving the stem cell state
(Fong et al., 2008). Since TRKC has been shown to be important
for maintaining hES cell survival, we sought to determine if
SOX2 could regulate TRKC expression in hES cells.
Our results show that hES cells do indeed express the genes
for the TRKB and TRKC receptors. Both the full-length and
truncated splice variants of the TRKC gene were expressed
at much higher levels than any splice variant of TRKB. Only
the truncated variant of TRKB was expressed at a very low
level. Previous studies have shown that truncated forms of
the TRKC receptor can still induce ligand-dependant signaling
in addition to the canonical signaling pathway (Esteban et al.,
2006). The high expression of both forms of TRKC indicates
that the gene may be important in maintaining survival and
self-renewal in hES cells.
Our results also show that the expression level of TRKC is
regulated by SOX2, as the loss of SOX2 resulted in considerable
downregulation of the TRKC gene.We also observed a decrease
in TRKC by immunocytochemistry indicating that the loss of
SOX2 was indeed reducing the amount of TRKC protein present
on the cell surface. The expression levels of TRKB, however,
were not significantly affected suggesting that SOX2 may not
be involved in the regulation of TRKB or that the level of
SOX2 reduction was insufficient in downregulating TRKB.
Analysis of the regulatory region of TRKC identified two
evolutionarily conserved SOX binding motifs. Our results from
the ChIP assays demonstrate that SOX2 interacts at this specific
region on the genome termed SOX Site A which contains a SOX
binding site. It also interacts minimally at a second site termed
SOX Site B. However, the level of enrichment at the Site B re-
gion is approximately 3-fold less than at Site A indicating that
Site A likely plays a greater role in the regulation of TRKC in
hES cells. The specificity for which SOX2 interacts with the
TRKC gene and the conservation of the SOX2 site indicates
that this site is important for regulation of the TRKC gene.
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tant for transcription of the TRKC gene as shown by luciferase
assays. Transfection of hES cells with TRKC-LUC Site A reporter
vector increased the fold change in luciferase activity by ap-
proximately 6-fold compared to cells transfected with just
the EMPTY-LUC vector. Including Site B in the reporter con-
struct, however, only increased luciferase activity slightly
over the EMPTY-LUC control. This difference in luciferase ac-
tivity with the inclusion of Site B could be due to the ability
of the site to bind repressors. In addition, it is likely that
some differences may exist between the endogenous TRKC
promoter and the TRKC promoter elements contained within
the reporter construct. Thus the construct may not behave
in a manner which entirely reflects the activity of the endoge-
nous gene in hES cells. Deletion of Site A, however, in hES cells
transfected with the TRKC-LUC Site delA construct decreased
activity to approximately 2-fold indicating that Site A is need-
ed to drive expression of the reporter gene. In the HFF-1 cells,
expression of SOX2was able to drive expression of the reporter
gene in the TRKC-LUC Site A vector. Deletion of Site A, howev-
er, dramatically decreased luciferase activity indicating that
SOX2 utilizes Site A to activate the TRKC promoter. Interest-
ingly, we observed an increase in luciferase activity in HFF-1
cells transfected with the TRKC-LUC Site A+B construct in
contrast to the activity observed when the construct was
transfected in hES cells. The disparity in activity may be due
to repressors binding to Site B present in hES cells that are
not present in the HFF-1 cells. However, further studies are
required to determine the activity at this site. Overall, our re-
sults in conjunction with the results of the ChIP assay show
that SOX2 utilizes Site A to produce a positive transcriptional
effect on the TRKC gene.
In conclusion, our findings reveal a novel regulatory rela-
tionship involving the survival gene TRKC and the transcription
factor SOX2. Our results indicate that SOX2 is important for
transcription of TRKC. To our knowledge, this study is the
first to report on the regulation of the TRKC gene by the tran-
scription factor SOX2. Further studiesmay be needed to clarify
the mechanism by which SOX2 is recruited to the TRKC pro-
moter and the method by which SOX2 determines specificity
for its target gene, specifically the identification of a binding
partner (Kamachi et al., 2000). This study, however, demon-
strates that SOX2 is indeed required for TRKC expression and
the importance of SOX2 in maintaining the properties of sur-
vival as well as self-renewal and pluripotency in hES cells.Materials and methods
Cell culture
H9 hES cells were cultured as described (Thomson et al.,
1998). Cells were grown on primary mouse embryo fibroblasts
(PMEFs) (Millipore, Billerica, MA) and passaged using 1 mg/ml
collagenase IV (Invitrogen, Carlsbad, CA). For feeder-free
conditions, hES cells were grown on plates coated with Matri-
gel (BD Biosciences, San Diego, CA) in mTeSR1 basal media
with the addition of mTeSR1 supplement (StemCell Technolo-
gies, Vancouver, Canada). For nucleofections, hES cells were
harvested using 0.05% trypsin-EDTA (Invitrogen) and an equal
amount of 1 mg/ml trypsin inhibitor (Invitrogen) added after
3 min. Nucleofected cells were cultured in neurotrophinsNT3, NT4, and BDNF (all from Peprotech, Rocky Hill, NJ) as
described (Pyle et al., 2006). HFF-1 cells (ATCC, Manassas,
VA) were cultured in Dulbecco's Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS),
1X GlutaMAX-I, and 1X MEM non-essential amino acids (all
from Invitrogen).
Transient transfections
For RNAi in hES cells, nucleofection was performed as previ-
ously described (Hohenstein et al., 2008). hES cells were
transfected with 100 μM of short interfering RNAs (siRNAs)
corresponding to SOX2 and β2M (Qiagen, Germantown,
MD). Target sequences, described previously, are as follows:
β2M, AAGATTCAGGTTTACTCACGT (Matin et al., 2004) and
SOX2: AAAACCAAGACGCTCATGAAG (Kondo and Raff, 2004).
In order to ensure efficient transfection of cells, initial exper-
iments included cotransfections of each siRNA with the
pmaxGFP vector (Lonza, Basel, Switzerland) at a ratio of 5:1.
RNA from knock down cells was collected 3–4 days following
nucleofection.
For luciferase assays, hES cells in 12-well tissue culture-
treated plateswere transfected as small colonies using Fugene
HD Transfection Reagent (Roche, Basel, Switzerland). A 2:1
ratio of Fugene HD to DNA was used to transfect a total of
1 μg of DNA for each condition. Cell lysates were harvested
24 h following transfection. HFF-1 cells in 12-well tissue
culture-treated plates were transfected at 70% confluency
using Lipofectamine 2000 (Invitrogen). A 1:5 ratio of DNA to
Lipofectamine 2000 was used to transfect a total of 2 μg
of DNA for each condition. Cell lysates were harvested
24 h following transfection.
RT-PCR and qRT-PCR analysis
RNA samples were prepared using the RNeasy Mini/Midi Kit
(Qiagen) and cDNA was synthesized using 1 μg total RNA
with the ABI High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Carlsbad, CA).
For analysis of TRK expression, PCR was performed on syn-
thesized cDNA using Taq DNA Polymerase (Qiagen). β-ACTIN
served as a control. Sequences and specifications are shown
in Supplementary Table 1.
For analysis of gene expression in siRNA-mediated knock
down experiments, qRT-PCR was performed in triplicate for
each primer set and each sample using an ABI 7900HT Sequence
Detection System. Amplification was performed using the
Taqman Universal PCR Mastermix (Applied Biosystems). Spe-
cific primers and probes for SOX2, TRKB, TRKC, and Eukaryotic
18 s rRNA were obtained from ABI (Taqman Gene Expression
Assays Hs01053049_s1, Hs01093103_m1, Hs00176797_m1,
and Hs99999901_s1, respectively). SOX2, TRKB, and TRKC
expression levels were normalized to Eukaryotic 18 s rRNA,
and then analyzed using the 2ΔΔCt method (Livak and
Schmittgen, 2001). Expression levels were calibrated relative
to RNA collected from hES cells transfected with no siRNA.
Immunocytochemistry
H9 hES cells were washed with 1× PBS (Invitrogen), fixed in
4% paraformaldehyde, and blocked in 10% serum and 0.5%
213Regulation of TRKC by SOX2Triton X-100 (Sigma) in PBS. Immunocytochemical analysis
was performed using a primary antibody to TRKC (Cell Sig-
naling, Danvers, MA) and an Alexa-conjugated secondary an-
tibody (Invitrogen). Both antibodies were diluted and used
according to the manufacturer's instructions. Cell nuclei
were counterstained with Hoechst (Invitrogen).ChIP assays
ChIP assays were performed in triplicate using 1.8×107 H9
hES cells for each sample as previously described (Zeng et
al., 2009). Chromatin extracts containing DNA fragments
sonicated to an average size of 500 bp were immunoprecipi-
tated using an anti-SOX2 antibody (R&D Systems, Minneapolis,
MN). Normal goat IgG (Abcam, Cambridge, MA) was used as an
isotypematched control to determine the level of non-specific
antibody binding. Mock ChIPs were also performed with no
antibody to serve as a negative control. Immunoprecipitated
DNA was purified using the QIAquick Gel Extraction Kit
(Qiagen) and analyzed by PCR and qRT-PCR. For PCR, Taq
DNA Polymerase Kit (Qiagen) was used to amplify ChIP DNA
with primers specific for SOX2 binding sites. Primers were
designed using Primer 3 (Rozen and Skaletsky, 2000) and
synthesized by IDT (Integrated DNA Technologies, San
Diego, CA). For qRT-PCR of ChIP DNA, SYBR green assays were
performed to determine fold enrichment of DNA (Applied
Biosystems). Standard and dissociation curves were also
performed to ensure high PCR efficiency and specific target
amplification. The fold enrichment of immunoprecipitated
DNA was calculated as previously described (Nelson et al.,
2006). Primer sequences for PCR and qRT-PCR are shown in
Supplementary Table 2.DNA constructs
For the TRKC-LUC Site A reporter vector, a 1.8 kb fragment of
the human TRKC regulatory region was amplified from 200 ng
of human genomic DNA (Promega, Madison, WI) using the fol-
lowing cloning primers: 5′-ACTACACTTGGCTGGGCAAAGAGA-
3′ and 5′-GATGCCAAGTGTGAGCTGTTTGCT-3′. For the TRKC-
LUC Site A+B reporter vector, a 2.5 kb fragment of the
human TRKC regulatory region was amplified from 200 ng of
human genomic DNA using the following cloning primers: 5′-
ACTACACTTGGCTGGGCAAAGAGA-3′ and 5′-CTCAGTTTCCTGA
CTCTCA-3′. The fragments were cloned into the pGEM-T Easy
cloning vector (Promega) and then excised using NcoI and
SacI restriction enzymes (NEB, Ipswich, MA). The excised
fragment was then cloned into the pGL4.10 reporter vector
(Promega) upstream of the firefly luciferase gene. The
TRKC-LUC Site delA construct was obtained from Genscript
USA Inc. (Genscript USA Inc, Piscataway, NJ).
The SOX2 expression vector (pBKCMV-SOX2) was generated
by excising the SOX2 cDNA from the vector backbone of pMIG-
hSOX2 (Park et al., 2008) (Addgene, Cambridge, MA) plasmid
using EcoRI and XhoI restriction enzymes (NEB). The excised
SOX2 fragment was cloned into the pBK-CMV expression vector
(Agilent, Santa Clara, CA) downstream of the CMV immediate
early promoter. All vectors were sequenced to verify presence
of the correct insert.Western blot
HFF-1 cells were collected for Western blotting by washing
one time with PBS (Invitrogen) followed by scraping with a
cell scraper. Cells were spun down in 1.5 ml microcentrifuge
tubes and lysed by the addition of SDS lysis buffer (0.5 M Tris
pH 6.8, 10% β-mercaptoethanol, 4% SDS, 20% glycerol with
Bromo blue) at 95 °C for 5 min. Thirty μl of the cell lysate
was electrophoresed onto 4–20% Tris–HCl polyacrylamide gel
(Bio-Rad, Hercules, CA) and transferred to a PVDF membrane
(GE Healthcare, Piscataway, NJ). Membranes were blocked
in 5% milk in Tris buffered saline-0.1% Tween-20 and probed
with an antibody to SOX2 (R&D Systems) followed by a horse-
radish peroxidase-conjugated secondary antibody (Santa
Cruz Biotechnology, Santa Cruz, CA). All antibodies were di-
luted according to themanufacturer's instructions and then vi-
sualized using an enhanced chemiluminescence kit (Bio-Rad)
on a Fujifilm LAS-4000 imaging system (Fujifilm Corpora-
tion, Valhalla, NY). Membranes were also probed with an an-
tibody to β-ACTIN (Santa Cruz Biotechnology) to ensure equal
loading and transfer.Luciferase assays
hES cells were transfectedwith 100 ng of the TRKC-LUC report-
er vector constructs and 5 ng of phRL-TK (Promega) for normal-
ization of transfection efficiency. HFF-1 cells were also
transfected with the same vectors in addition to 1 μg of the
expression vector pBKCMV-SOX2 or the empty expression
vector. pmaxGFP (Lonza) was used as stuffer DNA and to
gauge transfection efficiency. Cells were cultured for 24 h
following transfection and cell lysates were harvested
using Passive Lysis Buffer (Promega). Additionally, lysates
were subjected to two freeze-thaw cycles to achieve com-
plete cell lysis. Luciferase activities were then measured by
adding 100 μl of Luciferase Assay Reagent II followed by 100 μl
of Stop & Glo Reagent to 20 μl of the cell lysates (Promega).
All measurements were performed on a SIRIUS luminometer
(Berthold Detection Systems, Huntsville, AL). Assays were per-
formed in triplicate and each reading was performed twice.Acknowledgments
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